Acumen Research & Consulting estimates that global Liver Disease Diagnostics market is expected to reach the market value of around US$ 38.9 Bn by 2028 and is anticipated to grow at a CAGR of around 6.1% in terms of revenue during the forecast period 2021 - 2028.
In order to treat chronic and acute liver conditions, a series of blood tests called liver function tests is used. Various such blood checks can be done to diagnose a particular liver or genetic disorder. The imaging examination will be performed in an Ultrasound and CT, MRI scan, to display liver injury.
The report provides analysis of global Liver Disease Diagnostics market for the period 2017-2028, where in 2021 to 2028 is the forecast period and 2020 is considered as the base year.
Market Insights
One of the major reason that is projected to drive market of global liver diagnostic is the rising prevalence of acute and chronic liver diseases. The development of reliable diagnostic tools in order to enhance early detection and patient care outcomes will accelerate research and development by key industry players and will further fuel profit growth on this global market.
Furthermore, innovative methods for diagnosing hepatic diseases are projected to make a significant contribution to future business development. In fact, the global liver diagnostics industry will produce income growth for the attractive reimbursement plans under different health insurance schemes provided by the applicable governing bodies.
Hepatitis immunization and dietary changes eliminate liver cancer prevalence
Low mortality and the highly violent form of liver cancer have turned this illness into a global health concern worldwide. Hepatitis C virus (HBV) disease, diabetic cirrhosis, diabetes, obesity and hepatitis C virus (HCV) infection has been linked with multiple risk factors including liver cancer. Because these risk factors can be changed, a good promise has been presented for prevention approaches, including immunisation and improvements in lifestyles, to decrease their prevalence and mortality.
A number of deaths have occurred last year for liver cancer or hepatocellular carcinoma ( HCC). Experts around the world have developed a variety of advanced screening methods to prevent liver cancer from entering the final stage. New methods for diagnosing hepatocellular carcinoma have been developed to improve the health and performance of both partial hepatic and liver transplants. The creation of innovative, new technologies to completely detect liver cancer was concentrated on by global leading medical device manufacturers. It is expected that these factors fuel growth during the forecast span of the global liver cancer diagnostic industry.
Regional Stance
North America held major market share and is expected to grow at a steady CAGR amid the projected period in the liver disease diagnostics industry. Several reasons are likely to be responsible for increasing the liver diagnostic market in the region in large R&D investments and the involvement of key players. In fact, the presence of health care organizations is projected to drive the demand development of the diagnostics of liver disease. GetPalliativeCare.org offers palliative care information on medical procedures including endoscopy, CT scanning and biopsy, among other things.
The liver disease diagnostic market in the Asia Pacific is projected to grow significantly. Increasing geriatric population and knowledge of daily controls add to the market growth in the area for the treatment of liver disease. In addition, it would be expected to promote regional development through regulatory acceptance of emerging technology that can be combined with imaging systems. In August 2018, for example, LiverMultiScan was approved to treat patients suffering from highly prevalent illnesses in Australia.
Rising liver disease occurrence
Another important factor in the development of the liver disease industry is increased obesity, diabetes, and cardiovascular diseases. Furthermore, growing incidence of liver disease is projected to push the demand in the coming years due to side effects of certain drugs, such as acetaminophen and inadequate sanitary and sanitary conditions.
Key Players & Strategies
Participants include major global AstraZeneca, Bayer AG, Gilead Science Inc., Merck & Co. Inc, F. Hoffmann-La Roche AG, Sanofi, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Others.
Companies in the sectors pursue other significant projects to enhance their business position, such as marketing arrangements and corporate partnerships.
Market Segmentation
Liver Disease Diagnostics Market by Technique
Laboratory tests
Imaging
Biopsy
Endoscopy
Others
Liver Disease Diagnostics Market by End Use
Hospitals & Clinics
Laboratories
Others
Liver Disease Diagnostics Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
CHAPTER 1.Industry Overview of Liver Disease Diagnostics
1.1.Definition and Scope
1.1.1.Definition of Liver Disease Diagnostics
1.1.2.Market Segmentation
1.1.3.Years Considered for the Study
1.1.4.Assumptions and Acronyms Used
1.1.4.1.Market Assumptions and Market Forecast
1.1.4.2.Acronyms Used in Global Liver Disease Diagnostics Market
1.2.Summary
1.2.1.Executive Summary
1.2.2.Liver Disease Diagnostics Market By Technique
1.2.3.Liver Disease Diagnostics Market By End Use
1.2.4.Liver Disease Diagnostics Market by Regions
CHAPTER 2.Research Approach
2.1.Methodology
2.1.1.Research Programs
2.1.2.Market Size Estimation
2.1.3.Market Breakdown and Data Triangulation
2.2.Data Source
2.2.1.Secondary Sources
2.2.2.Primary Sources
CHAPTER 3.Market Dynamics And Competition Analysis
3.1.Market Drivers
3.1.1.Driver 1
3.1.2.Driver 2
3.2.Restraints and Challenges
3.2.1.Restrain 1
3.2.2.Restrain 2
3.3.Growth Opportunities
3.3.1.Opportunity 1
3.3.2.Opportunity 2
3.4.Porter’s Five Forces Analysis
3.4.1.Bargaining Power of Suppliers
3.4.2.Bargaining Power of Buyers
3.4.3.Threat of Substitute
3.4.4.Threat of New Entrants
3.4.5.Degree of Competition
3.5.Market Concentration Ratio and Market Maturity Analysis of Liver Disease Diagnostics Market
3.5.1.Go To Market Strategy
3.5.1.1.Introduction
3.5.1.2.Growth
3.5.1.3.Maturity
3.5.1.4.Saturation
3.5.1.5.Possible Development
3.6.Technological Roadmap for Liver Disease Diagnostics Market
3.7.Value Chain Analysis
3.7.1.List of Key Manufacturers
3.7.2.List of Customers
3.7.3.Level of Integration
3.8.Cost Structure Analysis
3.8.1.Price Trend of Key Raw Materials
3.8.2.Raw Material Suppliers
3.8.3.Proportion of Manufacturing Cost Structure
3.8.3.1.Raw Material
3.8.3.2.Labor Cost
3.8.3.3.Manufacturing Expense
3.9.Regulatory Compliance
3.10.Competitive Landscape, 2020
3.10.1.Player Positioning Analysis
3.10.2.Key Strategies Adopted By Leading Players
CHAPTER 4.Manufacturing Plant Analysis
4.1.Manufacturing Plant Location and Establish Date of Major Manufacturers in 2020
4.2.R&D Status and Application Source of Liver Disease Diagnostics Major Manufacturers in 2020
CHAPTER 5.Liver Disease Diagnostics Market By Technique
5.1.Introduction
5.2.Liver Disease Diagnostics Revenue By Technique
5.2.1.Liver Disease Diagnostics Revenue (US$ Mn) and Forecast, By Technique, 2017-2028
5.2.2.Laboratory tests
5.2.2.1.Laboratory tests Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.3.Imaging
5.2.3.1.Imaging Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.4.Biopsy
5.2.4.1.Biopsy Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.5.Endoscopy
5.2.5.1.Endoscopy Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
5.2.6.Others
5.2.6.1.Others Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
CHAPTER 6.Liver Disease Diagnostics Market Revenue By End Use
6.1.Introduction
6.2.Liver Disease Diagnostics Revenue (US$ Mn) By End Use
6.2.1.Liver Disease Diagnostics Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
6.2.2.Hospitals & Clinics
6.2.2.1.Hospitals & Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.3.Laboratories
6.2.3.1.Laboratories Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
6.2.4.Others
6.2.4.1.Others Market Revenue (US$ Mn) and Growth Rate (%), 2017-2028
CHAPTER 7.North America Liver Disease Diagnostics Market By Country
7.1.North America Liver Disease Diagnostics Overview
7.2.U.S.
7.2.1.U.S. Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
7.2.2.U.S. Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
7.3.Canada
7.3.1.Canada Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
7.3.2.Canada Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
7.4.North America PEST Analysis
CHAPTER 8.Europe Liver Disease Diagnostics Market By Country
8.1.Europe Liver Disease Diagnostics Market Overview
8.2.U.K.
8.2.1.U.K. Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
8.2.2.U.K. Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.3.Germany
8.3.1.Germany Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
8.3.2.Germany Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.4.France
8.4.1.France Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
8.4.2.France Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.5.Spain
8.5.1.Spain Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
8.5.2.Spain Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.6.Rest of Europe
8.6.1.Rest of Europe Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017-2028
8.6.2.Rest of Europe Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017-2028
8.7.Europe PEST Analysis
CHAPTER 9.Asia Pacific Liver Disease Diagnostics Market By Country
9.1.Asia Pacific Liver Disease Diagnostics Market Overview
9.2.China
9.2.1.China Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.2.2.China Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.3.Japan
9.3.1.Japan Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.3.2.Japan Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.4.India
9.4.1.India Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.4.2.India Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.5.Australia
9.5.1.Australia Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.5.2.Australia Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.6.South Korea
9.6.1.South Korea Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.6.2.South Korea Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.7.Rest of Asia-Pacific
9.7.1.Rest of Asia-Pacific Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
9.7.2.Rest of Asia-Pacific Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
9.8.Asia Pacific PEST Analysis
CHAPTER 10.Latin America Liver Disease Diagnostics Market By Country
10.1.Latin America Liver Disease Diagnostics Market Overview
10.2.Brazil
10.2.1.Brazil Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
10.2.2.Brazil Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.3.Mexico
10.3.1.Mexico Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
10.3.2.Mexico Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
10.4.Rest of Latin America
10.4.1.Rest of Latin America Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 – 2028
10.4.2.Rest of Latin America Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
CHAPTER 11.Middle East & Africa Liver Disease Diagnostics Market By Country
11.1.Middle East & Africa Liver Disease Diagnostics Market Overview
11.2.Saudi Arabia
11.2.1.Saudi Arabia Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
11.2.2.Saudi Arabia Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
11.3.UAE
11.3.1.UAE Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
11.3.2.UAE Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
11.4.Rest of Middle East & Africa
11.4.1.Rest of Middle East & Africa Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By Technique, 2017 - 2028
11.4.2.Rest of Middle East & Africa Liver Disease Diagnostics Market Revenue (US$ Mn) and Forecast By End Use, 2017 - 2028
CHAPTER 12.Player Analysis Of Liver Disease Diagnostics
12.1.Liver Disease Diagnostics Market Company Share Analysis
12.2.Competition Matrix
12.2.1.Competitive Benchmarking of key players by price, presence, market share, and R&D investment
12.2.2.New Product Launches and Product Enhancements
12.2.3.Mergers And Acquisition In Global Liver Disease Diagnostics Market
12.2.4.Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13.COMPANY PROFILE
13.1.AstraZeneca
13.1.1.Company Snapshot
13.1.2.Business Overview
13.1.3.Financial Overview
13.1.3.1.Revenue (US$ Mn), 2020
13.1.3.2.AstraZeneca 2020 Liver Disease Diagnostics Business Regional Distribution
13.1.4.Product/ Service and Specification
13.1.5.Recent Developments & Business Strategy
13.1.6.Manufacturing Plant Footprint Analysis
13.2.Bayer AG
13.3.Gilead Science Inc.
13.4.Merck & Co. Inc
13.5.F. Hoffmann-La Roche AG
13.6.Sanofi
13.7.Pfizer Inc.
13.8.Novartis AG
13.9.GlaxoSmithKline plc
13.10.Others